Melville, NY (PRWEB) July 03, 2012
Long Island IVF is one of five U.S. fertility clinics recruiting patients for a randomized controlled trial using 24sure Array CGH (comparative genomic hybridization), a type of preimplantation genetic screening (PGS), to select chromosomally normal embryos for transfer in an in vitro fertilization cycle. Women between the ages of 33 and 42 years old may participate in the study, which will evaluate the effectiveness of the array CGH when compared with standard embryo selection in IVF.
“With advancing maternal age, more embryos have chromosomal abnormalities - from 60 percent in women younger than 35 to 80 percent in women 40 and older. This may result in embryos failing to implant, miscarriage or babies born with conditions such as Down syndrome,” says Dr. Daniel Kenigsberg, a reproductive endocrinologist and co-founder of Long Island IVF. “Such chromosomal abnormalities are also thought to be a major cause of IVF failure.”
Because of the likelihood of chromosomal abnormalities, reproductive endocrinologists often select two or more embryos to transfer during an IVF cycle. Transferring two or more embryos puts the woman at risk of becoming pregnant with twins and the ensuing risks of premature birth, congenital abnormalities and developmental problems.
24sure is a new technology, developed by BlueGnome, which screens embryos for the correct number of chromosomes in order to select a single, normal embryo for transfer. The researchers will compare a control group (standard of care), who will have up to two embryos transferred on day 5 based on developmental characteristics, with a test group who will have blastocysts biopsied on day 5, screening performed with 24sure, and a single chromosomally normal embryo transferred on day 6. This study will assess whether single embryo transfer IVF with PGS delivers the same or superior pregnancy rates to multiple embryo transfer IVF without screening.
“Observational studies have indicated that the number of embryos that will implant will be higher in the PGS group and that the miscarriage rate will be reduced,” says Dr. Kenigsberg. “However, there have been no suitable randomized controlled trials to verify this.”
To qualify for the study, you must:
- Be a healthy, pre-menopausal female, 33-42 years of age
- Agree to be randomly assigned to either the arm of the study receiving array CGH (test arm) or the arm receiving no additional testing (Control arm)
If you participate in the study, the preimplantation genetic screening is free. If you are allocated to the control group and do not become pregnant you will be offered PGS for free in your next cycle. For more information or to see if you are eligible, contact: Eva Schenkman (631) 881-5337